Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
3/20/2026, 12:00:00 AM
U.S. FDA approved Opdivo (nivolumab) in combination with AVD for the first-line treatment of adult and pediatric patients with previously untreated, Stage III or IV classical Hodgkin Lymphoma.
Korean Translation
미국 FDA, 이전에 치료받지 않은 3기 또는 4기 전형적 호지킨 림프종 성인 및 소아 환자의 1차 치료를 위해 옵디보(니볼루맙)와 AVD 병용 요법을 승인함.
Related Recent Events
Micron Technology Inc. (MU) · Earnings Release
Micron's fiscal third-quarter 2026 earnings release is scheduled for June 24, 2026, scheduled. High importance is estimated as earnings releases for major semiconductor companies typically result in price impacts exceeding 10%.
6/24/2026, 12:00:00 AM
Apple Inc (AAPL) · Other
Apple's annual Worldwide Developers Conference (WWDC) is scheduled to begin on June 8, 2026, to unveil iOS 27 and major AI advancements; these updates are estimated to have a >5% price impact scheduled
6/8/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Hewlett Packard Enterprise Co is expected to announce its Q2 2026 earnings results on June 2, 2026 scheduled.
6/2/2026, 12:00:00 AM
NetApp Inc (NTAP) · Earnings Release
Q4 2026 earnings release including analyst EPS forecasts of $2.25-$2.27 forecasted, scheduled. Medium importance estimated as quarterly earnings are major catalysts for this stock.
5/28/2026, 12:00:00 AM
Palo Alto Networks Inc (PANW) · Earnings Release
Palo Alto Networks' next earnings release for Q3 2026 is scheduled for May 19, 2026. Low importance as it is a routine scheduled announcement with no results yet, scheduled.
5/19/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Next earnings release for Q1 2026 is scheduled for 2026-05-14, with analysts forecasting an EPS of -$0.04. A neutral impact is expected as the market typically waits for actual results, so the release is forecasted and scheduled.
5/14/2026, 12:00:00 AM